The study identifies the first function of the BMPR-II tail domain, suggesting that deregulation of actin dynamics via LIMK1 may contribute to the etiology of primary pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
May link LIMK1-cofilin dysregulation to pulmonary hypertension pathogenesis; leaves open therapeutic relevance pending human validation.
Bone morphogenetic proteins (BMPs) regulate multiple cellular processes, including cell differentiation and migration. Their signals are transduced by the kinase receptors BMPR-I and BMPR-II, leading to Smad transcription factor activation via BMPR-I. LIM kinase (LIMK) 1 is a key regulator of actin dynamics as it phosphorylates and inactivates cofilin, an actin depolymerizing factor. During a search for LIMK1-interacting proteins, we isolated clones encompassing the tail region of BMPR-II. Although the BMPR-II tail is not involved in BMP signaling via Smad proteins, mutations truncating this domain are present in patients with primary pulmonary hypertension (PPH). Further analysis revealed that the interaction between LIMK1 and BMPR-II inhibited LIMK1's ability to phosphorylate cofilin, which could then be alleviated by addition of BMP4. A BMPR-II mutant containing the smallest COOH-terminal truncation described in PPH failed to bind or inhibit LIMK1. This study identifies the first function of the BMPR-II tail domain and suggests that the deregulation of actin dynamics may contribute to the etiology of PPH.
No takes yet. Share an insight, caveat, or question.
Foletta et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: